MANCHESTER KEITH S — SEC Form 4 filings
SEC reporting owner CIK 1244828. 12 Form 4 filings on record with FilingPulse; latest filed 2026-09-18.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-03-07 to 2026-09-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 23 legs across 6 filings — 6,370,407 shares, $160,371,253 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 17.
- Largest priced transaction: sale of 600,000 shares @ $34.59 ($20,754,000) in Roivant Sciences Ltd., filed 2026-06-30.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | Director | 10 | — | 22 legs · 6,361,561 sh · $160,338,616 | 14 |
| Arbutus Biopharma Corp (ABUS) | Director | 2 | — | 1 leg · 8,846 sh · $32,637 | 3 |
Form 4 filings — MANCHESTER KEITH S
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 5,054 @ $0 · Grant/award (A): 10,531 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Roivant Sciences Ltd. (ROIV) | Sale (S): 300,783 @ $33.92 · Sale (S): 325,000 @ $34.07 · Sale (S): 200,000 @ $34.44 · Sale (S): 600,000 @ $34.59 · Sale (S): 12,380 @ $35.28 · Sale (S): 200,000 @ $35.45 | EDGAR |
| 2026-02-13 | 4 | Roivant Sciences Ltd. (ROIV) | Sale (S): 425,000 @ $26.67 · Sale (S): 150,000 @ $26.72 · Sale (S): 275,000 @ $26.76 · Sale (S): 150,784 @ $26.49 · Sale (S): 225,000 @ $26.50 | EDGAR |
| 2025-12-18 | 4 | Roivant Sciences Ltd. (ROIV) | Sale (S): 275,000 @ $22.93 · Sale (S): 642,282 @ $23.08 · Sale (S): 432,718 @ $23.05 · Sale (S): 155,076 @ $23.02 · Sale (S): 189,538 @ $23.17 | EDGAR |
| 2025-11-21 | 4 | Roivant Sciences Ltd. (ROIV) | Sale (S): 850,000 @ $20.25 · Sale (S): 150,000 @ $20.20 · Sale (S): 125,000 @ $20.16 · Sale (S): 175,000 @ $20.24 | EDGAR |
| 2025-09-12 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 14,524 @ $0 · Grant/award (A): 33,726 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Roivant Sciences Ltd. (ROIV) | Other (J): 6,205,368 @ $0 · Other (J): 3,176,245 @ $0 · Other (J): 6,837,266 @ $0 · Other (J): 1,170,646 @ $0 | EDGAR |
| 2024-09-26 | 4 | Roivant Sciences Ltd. (ROIV) | Sale (S): 368,052 @ $11.62 · Sale (S): 134,948 @ $11.77 | EDGAR |
| 2024-09-12 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 16,406 @ $0 · Grant/award (A): 27,894 (derivative) @ $0 | EDGAR |
| 2024-08-16 | 4 | Arbutus Biopharma Corp (ABUS) | Option exercise (M): 54,915 @ $0.56 · Sale (S): 8,846 @ $3.69 · Option exercise (M): 54,915 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | Arbutus Biopharma Corp (ABUS) | Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2024-03-07 | 4 | Roivant Sciences Ltd. (ROIV) | Other (J): 11,077,765 @ $0 · Other (J): 11,325,233 @ $0 · Other (J): 5,594,064 @ $0 · Other (J): 2,260,661 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1244828 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →